GLA-SE adjuvant

Phase 2Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

GLA-SE adjuvant is one of 3 biologic programs targeting HIV Prevention. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV PreventionNot yet recruiting

HIV PreventionPhase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in HIV Prevention

#DrugCompanyPhaseTrials

GLA-SE adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 2

Alhydrogel Adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 3

Pre-Exposure Prophylaxis (prep)

NNew York University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Not yet recruiting

HIV Prevention

NCT07675629

Clinical

Trials by Indication[1]

Immunogenicity3 trials

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03220724·117 enrolled

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03409276·60 enrolled

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Completed·WWorcester HIV Vaccine·Phase 1·NCT04927585·42 enrolled

Immune Response1 trial

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Completed·HHIV Vaccine Trials Network·Phase 1·NCT04607408·38 enrolled

HIV Prevention1 trial

Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A, B, C, A/E) / Gag (C) DNA and gp120 (A, B, C, A/E) Protein HIV-1 Vaccines (PDPHV) With Either Alhydrogel or GLA-SE in Healthy Adults Living Without HIV

Not yet recruiting·WWorcester HIV Vaccine·Phase 2·NCT07675629·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GLA-SE adjuvant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLA-SE adjuvant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLA-SE adjuvant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

GLA-SE adjuvant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Immunogenicity3 trials

Immune Response1 trial

HIV Prevention1 trial

References

Drug Info

Quick Facts

Related News